ASXL1 and acute myeloid leukemia: We identified the recurrent MH-based deletion in ASXL1 in three of 124 pre-AML cases 10.7, 8.8 and 1.7 years prior to AML diagnoses (Supplementary Table 1) and none among the 676 controls14.